Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Aug 11;7(8):e016999.
doi: 10.1136/bmjopen-2017-016999.

Multicentric randomised study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study

Marcis Leja  1   2   3 , Jin Young Park  4 , Raul Murillo  4 , Inta Liepniece-Karele  1   2   5 , Sergejs Isajevs  1   2   5 , Ilze Kikuste  1   3 , Dace Rudzite  1   2 , Petra Krike  1 , Sergei Parshutin  1   6 , Inese Polaka  1   6 , Arnis Kirsners  1   6 , Daiga Santare  1   2 , Valdis Folkmanis  1 , Ilva Daugule  1 , Martyn Plummer  7 , Rolando Herrero  4
Affiliations
Randomized Controlled Trial

Multicentric randomised study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study

Marcis Leja et al. BMJ Open. .

Abstract

Introduction: Population-based eradication of Helicobacter pylori has been suggested to be cost-effective and is recommended by international guidelines. However, the potential adverse effects of widespread antibiotic use that this would entail have not been sufficiently studied. An alternative way to decrease gastric cancer mortality is by non-invasive search for precancerous lesions, in particular gastric atrophy; pepsinogen tests are the best currently available alternative. The primary objective of GISTAR is to determine whether H pylori eradication combined with pepsinogen testing reduces mortality from gastric cancer among 40-64-year-old individuals. The secondary objectives include evaluation of H pylori eradication effectiveness in gastric cancer prevention in patients with precancerous lesions and evaluation of the potential adverse events, including effects on microbiome.

Methods and analysis: Individuals are recruited from general population (50% men) in areas with high gastric cancer risk in Europe and undergo detailed lifestyle and medical history questionnaire before being randomly allocated to intervention or control groups. The intervention group undergoes H pylori testing and is offered eradication therapy if positive; in addition, pepsinogen levels are detected in plasma and those with decreased levels are referred for upper endoscopy. All participants are offered faecal occult blood testing as an incentive for study participation. Effectiveness of eradication and the spectrum of adverse events are evaluated in study subpopulations. A 35% difference in gastric cancer mortality between the groups is expected to be detectable at 90% power after 15 years if 30 000 individuals are recruited. Biological materials are biobanked for the main and ancillary studies. The study procedure and assumptions will be tested during the pilot phase.

Ethics and dissemination: The study was approved by the respective ethics committees. An independent Data Safety and Monitoring Board has been established. The findings will be published in peer-reviewed journals and presented at scientific meetings.

Trial registration number: NCT02047994.

Keywords: Eradication; Gastric Cancer; H. Pylori; Pepsinogen; Prevention; Randomised Study.

PubMed Disclaimer

Conflict of interest statement

Competing interests: ML is a partner in institutions involved in realisation of the project—Digestive Diseases Centre GASTRO and Academic Histology laboratory. ILK and SI are employees of Academic Histology Laboratory, IK—of Digestive Diseases Centre GASTRO. Otherwise, the authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
GISTAR general study design.
See this image and copyright information in PMC

References

    1. Herrero R, Parsonnet J, Greenberg ER. Prevention of gastric cancer. JAMA 2014;312:1197–8. 10.1001/jama.2014.10498 - DOI - PubMed
    1. Forman D, Sierra M S. The current and projected global burden of gastric cancer IARC Helicobacter pylori Working Group Helicobacter pylori Eradication as a Strategy for preventing gastric Cancer Lyon, France: International Agency for Research on Cancer (IARC working Group Reports, no 8):5-–15. http://wwwiarcfr/en/publications/pdfs-online/wrk/wrk8/indexphp2014.
    1. Jemal A, Bray F, Center MM, et al. . Global cancer statistics. CA Cancer J Clin 2011;61:69–90. 10.3322/caac.20107 - DOI - PubMed
    1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765–81. 10.1016/j.ejca.2009.12.014 - DOI - PubMed
    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374–403. 10.1016/j.ejca.2012.12.027 - DOI - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources